Panacea Pharmaceuticals, MIT, Eksigent Technologies, Inpharmatica, British Biotech

Sep 12, 2003

Premium

Panacea Pharma Expands MIT Antibody Collaboration

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

Biden Cancer Initiative Suspends Work

The nonprofit Biden Cancer Initiative is suspending its operations, according to the Associated Press.

Not What Was Expected, Eh?

Researchers examine how white nationalists handle personal genetic ancestry results that conflict with their racist worldview, the New York Times reports.

And Now You Know

NPR speaks with research participants before and after they learn their APOE E4 status, which affects their risk of developing Alzheimer's disease.

PLOS Papers Tackle Toxoplasma in Senegal, CCHFV in Sudan, More

In PLOS this week: genetic characterization of Toxoplasma gondii strains, Crimean-Congo Hemorrhagic Fever Virus uncovered in Sudan, and more.

Featured White Papers

AlbuVoid Enrichment & Antibody Depletion – Tackling the Challenges of Serum Proteomics Part II

Stroma Liquid Biopsy, a pan-cancer biomarker panel of dysregulation derived from blood

Lipid Removal Sample Prep for Cell Response Applications

Jul

17

Featured Webinar

Expert Tips on Running a Mass Spec Core Lab Amid Rapid Technological Change

In this webinar, three experts will share advice on how to efficiently manage a mass spectrometry core lab while staying ahead of the technology curve.

Aug

22

Featured Webinar

Biobanks and the Rise of Precision Medicine: Lessons from the Estonian Biobank

This webinar will discuss how the Estonian Biobank, a cohort of more than 165,000 participants, is addressing industry challenges with data management and collaboration in the transition to precision medicine.

Menu